DCM Shriram Fine Chemicals posts Q1FY27 profit of ₹2.4 crore; appoints Rudra Shriram as MD
DCM Shriram Fine Chemicals posted a standalone net profit of ₹2.42 crore in Q1FY27, reversing a ₹4.08 crore loss in the previous quarter. Consolidated profits reached ₹2.59 crore. Revenue declined 8% YoY to ₹9,160 lakh but improved sequentially. The board appointed Rudra Shriram as MD and Rakesh Malhotra as Independent Director.

*this image is generated using AI for illustrative purposes only.
DCM Shriram Fine Chemicals Limited returned to profitability in the first quarter of FY27, reporting a standalone net profit of ₹2.42 crore for the period ended June 30, 2026. This marks a significant turnaround from the net loss of ₹4.08 crore recorded in the immediately preceding quarter (Q4FY26). On a consolidated basis, the company reported a net profit of ₹2.59 crore, compared to a consolidated loss of ₹3.83 crore in Q4FY26.
Revenue from operations showed a slight contraction year-on-year but stabilized sequentially. Standalone total income from operations for Q1FY27 was ₹9,159.96 lakh, down from ₹9,928.67 lakh in the same quarter last year (Q1FY26). However, this represented an improvement from the ₹9,351.29 lakh logged in Q4FY26. Consolidated total income from operations stood at ₹9,184.13 lakh.
Leadership Changes
In a significant governance development, the Board of Directors approved several key personnel changes during its meeting on August 14, 2026:
- Resignation: Mr. Akshay Dhar resigned from his positions as Managing Director and CEO effective close of business hours on August 14, 2026. The company stated he is stepping away from day-to-day management to focus on leading new projects and expansion initiatives.
- New Appointment: Mr. Rudra Shriram, son of Chairman Alok B Shriram, was inducted as an Additional Director and appointed Managing Director for a five-year term effective August 15, 2026. He currently serves as Deputy Managing Director at DCM Shriram International Limited.
- Independent Director: Mr. Rakesh Malhotra was appointed as an Additional Director in the category of Non-Executive Independent Director for a five-year term, subject to member approval.
What the Numbers Show
The return to profitability was driven by a combination of reduced expenses and higher other income, despite a slight dip in core sales. Standalone other income rose to ₹81.86 lakh in Q1FY27 from ₹43.18 lakh in Q4FY26, contributing significantly to the bottom line given the thin operating margins.
Operating expenses remained relatively stable, with total expenses at ₹8,806.91 lakh in Q1FY27 compared to ₹9,833.47 lakh in Q4FY26. Notably, cost of materials consumed increased to ₹6,067.65 lakh from ₹5,693.39 lakh in the previous quarter, while employee benefits expense remained flat at ₹1,221.19 lakh. The reduction in overall expenses, coupled with the rise in other income, allowed the company to bridge the gap between revenue and costs, resulting in a pre-tax profit of ₹3.53 lakh versus a pre-tax loss of ₹4.82 lakh in Q4FY26.
| Metric | Q1FY27 (Standalone) | Q4FY26 (Standalone) | Q1FY26 (Standalone) |
|---|---|---|---|
| Total Income from Operations | ₹9,159.96 lakh | ₹9,351.29 lakh | ₹9,928.67 lakh |
| Other Income | ₹81.86 lakh | ₹43.18 lakh | ₹66.80 lakh |
| Total Expenses | ₹8,806.91 lakh | ₹9,833.47 lakh | ₹9,374.39 lakh |
| Profit Before Tax | ₹3.53 lakh | -₹4.82 lakh | ₹5.54 lakh |
| Net Profit | ₹2.42 lakh | -₹4.08 lakh | ₹4.13 lakh |
The financial results were reviewed by Kirtane & Pandit LLP, the statutory auditors, who issued an unmodified conclusion. The results have been prepared in accordance with Ind AS 34 and Regulation 33 of the SEBI LODR Regulations.
Historical Stock Returns for DCM Shriram Fine Chemicals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.09% | +0.42% | +4.34% | -9.88% | 0.0% | 0.0% |
How will the transition of leadership to Rudra Shriram impact DCM Shriram Fine Chemicals' strategic focus on new projects and expansion initiatives?
Given that profitability was driven largely by other income rather than core sales growth, what operational measures are being taken to improve thin operating margins in Q2FY27?
Will the appointment of Rakesh Malhotra as an Independent Director bring specific governance changes or expertise relevant to the fine chemicals sector?

































